Table 2.

Univariate survival analysis of OS and DFS in 162 patients with EOC

Variables	OS			P-valuea	DFS		P-valuea
	Mean ± SE (months)		95% CI		Mean ± SE (months)	95% CI
Age (years)
≤55	82	38±2	34–43	P=0.129	33±2	29–37	P=0.089
>55	80	46±3	40–51		40±3	34–45
Histological cell type
Serous	118	42±2	38–45	P=0.164	35±2	32–38	P=0.449
Nonserous	44	40±4	32–48		40±4	31–48
FIGO stage
III	135	48±2	44–52	P<0.001	41±2	38–45	P<0.001
IV	27	17±1	14–19		14±1	12–16
Histological grade
G1	92	53±3	47–58	P<0.001	45±2	41–50	P<0.001
G2/G3	70	29±2	26–32		25±2	22–28
CA-125 (U/mL−1)
≤35	55	49±4	42–57	P=0.016	44±4	37–51	P=0.009
>35	107	38±2	35–41		33±2	30–36
Residual tumor (cm)
≤1	120	50±2	46–54	P<0.001	43±2	39–47	P<0.001
>1	42	23±2	20–26		20±2	17–23
Lymph node metastasis
No	117	46±2	42–50	P=0.004	40±2	36–44	P=0.001
Yes	45	34±4	27–42		28±3	22–33
AEG-1 expression
Low expression	54	62±3	56–67	P<0.001	55±3	50–60	P<0.001
High expression	108	31±1	28–34		26±1	24–29

Note:

^aLog-rank test.

Abbreviations: AEG-1, astrocyte-elevated gene-1; CA-125, cancer antigen 125; CI, confidence interval; DFS, disease-free survival; EOC, epithelial ovarian cancer; FIGO, International Federation of Gynecology and Obstetrics; G1, well differentiated; G2, moderately differentiated; G3, poorly differentiated; OS, overall survival; SE, standard error.